Genomic alterations as predictive biomarkers for cancer-associated thrombosis (CAT) in biliary tract cancer (BTC).
Angelo Pirozzi(Humanitas University), Mitesh J. Borad(Jacksonville College), Naohiro Okano(Kyorin University), Umair Majeed(Mayo Clinic in Florida), Binbin Zheng-Lin(WinnMed), Nguyen H. Tran(Mayo Clinic), Cody Eslinger(WinnMed), Hani M. Babiker, Tanios Bekaii‐Saab(WinnMed), Celine Hoyek(Mayo Clinic Hospital), Surbhi Shah(WinnMed), Lorenza Rimassa(Humanitas University), Oluseyi Abidoye(Mayo Clinic)
Cited by 1
Related Papers
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles
|Cell Reports|2017|619
Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers
|JAMA Oncology|2019|472
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study
|The Lancet. Gastroenterology & hepatology|2021|423